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Background: Elevation of liver enzymes in rheumatoid arthritis patients treated with 
tocilizumab (Actemra®) or anakinra (Kineret®) is a well-documented phenomenon. However, 
characterization of liver histology has not been defined in most cases. Similarly, the factors 
involved in decisions regarding discontinuation of treatment and outcome have not been 
discussed in the literature to any significant extent.
Cases: Two women with rheumatoid arthritis refractory to standard therapies are reported here. 
One was treated with tocilizumab and the other with anakinra, and both developed toxic liver 
effects. Liver biopsy in both cases showed focal necrosis of hepatocytes – a hallmark of drug 
toxicity – with steatosis and early fibrosis. Inflammatory infiltrates were prominent in the patient 
treated with anakinra but not in the tocilizumab-treated patient. However, FibroTest (Assistance 
publique – Hôpitaux de Paris, Paris, France) in the latter patient showed an inflammatory activity 
of A2 and was staged as F2, and the histology also showed hemorrhagic areas. Although both 
patients were overweight and both had been exposed to steroids, the steatosis and steatohepatitis 
were considered to be related to drug hepatotoxicity. Other possible etiologies for liver injury 
were excluded. Discontinuation of anakinra led to rapid normalization of liver enzymes. The 
patient receiving tocilizumab developed hepatosplenomegaly but had normal liver enzymes. 
In spite of the hepatosplenomegaly, the tocilizumab treatment was continued since the patient 
had not responded to other drugs. There was a good response to the tocilizumab treatment and 
the liver biopsy showed only insignificant, reversible liver injury. At follow-up at 6-months 
the patient remains stable.
Conclusion: As cases showing tocilizumab or anakinra liver toxicity are appearing more 
  frequently to the authors, a full assessment for liver injury is recommended in patients given those 
drugs, with careful consideration of the decision to continue or discontinue treatment.   Further 
studies with long-term follow-up analysis are mandatory to guide appropriate management 
strategies.
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Introduction
Based on well-described efficacy and safety studies, tocilizumab (Actemra®; Hoffman-La 
Roche, Basel, Switzerland) and anakinra (Kineret®; Amgen Inc, Thousand Oaks, CA) 
have been approved for the treatment of rheumatoid arthritis in adults.1–3 Tocilizumab 
is a recombinant humanized anti-human interleukin-6 (IL-6) receptor monoclonal 
antibody and anakinra is an interleukin-1 (IL-1) receptor antagonist.2 Both drugs block 
inflammation and cartilage degradation associated with rheumatoid arthritis.4 Both 
tocilizumab and anakinra have been reported as being safe and well tolerated for up to Clinical Pharmacology: Advances and Applications 2011:3 submit your manuscript | www.dovepress.com
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3 years of continuous use in a diverse population of patients 
with rheumatoid arthritis.1,2,5,6 They are given parenterally 
and may cause pain at the injection site. Other common 
reactions include headache, nausea, and   flu-like symptoms.1,5 
The most frequent serious adverse events are arthralgia 
and progression of the rheumatoid arthritis.1 Other adverse 
events may include infections, particularly pneumonia and 
upper respiratory infections, fractures, sinusitis, and diarrhea. 
Sepsis and opportunistic infection such as Mycobacterium 
or histoplasmosis are occasionally reported.1,2,5 In a large 
study of 1346 patients treated with tocilizumab or anakinra, 
a total of 15 fatalities occurred over 3 years of therapy.2 
Events in the fatal cases included cardiac arrest, myocardial 
infarction, cerebrovascular accident, ventricular fibrillation, 
sepsis, upper gastrointestinal hemorrhage, malignant 
melanoma, lymphoma, and suicide.1,2,4
Liver injury in patients treated with both drugs is well 
recognized, and increased transaminases and serum bilirubin 
levels have been reported.1,2,5 In most cases of treatment 
with tocilizumab, the liver injury resolved or was alleviated 
following cessation or reduction in the dose of the drug.1–3,5 
In general, neither the alaninaminotransferase elevations 
nor the increase in bilirubin were associated with clinical 
evidence of hepatic insufficiency.1 Indeed, in many cases 
there were other possible etiologies for the disturbance in 
liver function, such as autoimmune hepatitis, steroid-induced 
steatohepatitis, and even other drug-induced hepatotoxicities, 
particularly methotrexate (MTX).1,7 Although adverse effects 
of tocilizumab on the liver have been reported, histological 
evaluation of the liver pathology has not been documented. 
The current report presents two patients with rheumatoid 
arthritis, with hepatotoxicity that may have been induced by 
tocilizumab and anakinra (Table 1).
Case 1
A 46-year-old female who was first diagnosed as suffering 
from rheumatoid arthritis in May 2000. As nonsteroidal 
anti-inflammatory drugs (NSAIDs) were not effective, she 
was treated with MTX 12.5 mg once weekly for 10 years. 
She developed progressive arthralgia and severe morning 
stiffness, and only high dosage systemic steroids succeeded 
in controlling the symptoms. MTX was discontinued, as it 
had ceased to become effective and did not achieve steroid 
sparing. In June 2009 she was treated with three courses of 
infliximab (Remicade®; Janssen Biotech, Inc, Horsham, PA) 
against antitumor necrosis alpha (TNFα). This was admin-
istered in a dose of 5 mg/kg (ie, 5 mg × 80 kg = 400 mg) at 
weeks 0, 2, and 6 but did not result in clinical improvement. 
In January 2010, 6 months after the final course of infliximab, 
treatment was started with intravenous infusions of tocili-
zumab at a dose of 8 mg/kg (ie, 640 mg) – the maximal 
recommended dose. The patient received two infusions 
1 month apart and then continued on a maintenance dose 
of 4 mg/kg (320 mg) monthly by intravenous infusion. She 
experienced a good response, with significant improvement 
in the arthralgia and morning stiffness.
Prior to tocilizumab administration, her total white blood 
cell count (measured in cells per cubic millimeter [cmm]) 
was 7000/cmm (77% neutrophils), hemoglobin 14 g/dL, 
and platelet count 178,000/cmm. Full biochemical analy-
Table 1 Patient characteristics
Baseline patient features Case 1 Case 2
Age 46 49
Year of diagnosis 2000* 1998*
Sex Female Female
Medical history None Infertility, hypertension, fatty liver
Previous treatment for rheumatoid arthritis NSAIDs, MTX, Remicade®** NSAIDs, MTX
Baseline laboratory tests GOT = 22 U/L 
GPT = 18 U/L 
LDH = 250 U/L 
GGT = 25 U/L 
WBC (neutrophils %) = 7000 (77%) 
HB = 14 g/dL 
PLT = 178,000/cmm
GOT = 16 U/L 
GPT = 16 U/L 
LDH = 364 U/L 
GG = 21 U/L 
WBC (Neutrophils %) = 9,500 (60%) 
HB = 13.5 g/dL 
PLT = 221,000/cmm
Concomitant medications None Atenolol
Body mass index 25 31
Alcohol consumption None None
History of liver disease None Nonalcoholic fatty liver disease
Notes: *American Rheumatism Association criteria13; **Remicade® (Janssen Biotech, Inc, Horsham, PA) against antitumor necrosis alpha (TNFα). 
Abbreviations:  NSAIDs,  nonsteroidal  anti-inflammatory  drugs;  MTX,  methotrexate;  GOT,  glutamic  oxaloacetic  transaminase;  GPT,  glutamic  pyruvic  transaminase;   
LDH, lactate dehydrase; GGT, gamma glutamyl transpeptidase; ALP, alkaline phosphatase; WBC, white blood cell; PLT, platelets; HB, hemoglobin.Clinical Pharmacology: Advances and Applications 2011:3 submit your manuscript | www.dovepress.com
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sis, including serum transaminases (glutamic oxaloacetic 
transaminase [GOT], glutamic pyruvic transaminase [GPT], 
lactate dehydrase [LDH], gamma glutamyl transpeptidase 
[GGT], and alkaline phosphatase [ALP]) were all within 
the normal ranges.
In February 2010, she started to complain of generalized 
weakness and fatigue. Laboratory tests at the time remained 
within normal limits. Abdominal ultrasound showed mild 
fatty liver as well as mild splenomegaly. Investigation of fatty 
liver disease and splenomegaly revealed negative (normal) 
results for serum hepatitis B surface antigen, anti-hepatitis 
C virus, human immunodeficiency virus, cytomegalovirus 
immunoglobulin M, Epstein-Barr virus immunoglobulin M, 
antinuclear antibodies, and anti-liver-kidney microsome 
  antibodies. Serum ceruloplasmin, ferritin, thyroid-s  timulating 
hormone, and glycated hemoglobin levels were also within 
normal limits. There was no history of other drug or herbal 
administration, no alcohol consumption, and no family 
history of liver disease.
On physical examination, the patient was found to be 
overweight; body mass index was 25, which is mildly 
elevated. Apart from mild splenomegaly, the physical 
examination was unremarkable, with no other stigmata of 
chronic liver disease. Liver biopsy on July 2010 revealed 
focal hemorrhagic necrosis of hepatocytes with zones of 
macrovesicular steatosis and perisinusoidal fibrosis but no 
evidence of inflammation or cellular infiltrate (Figure 1). 
There was no evidence of hepatitis or any other cause of 
hepatotoxicity, and the histological findings of steatosis 
and focal necrosis were attributed to the tocilizumab. Fibro 
Test indicated injury activity of A1, and was also scored as 
a fibrosis index of F1. As the patient had failed to respond 
to all other therapeutic modalities it was decided to continue 
the tocilizumab. This decision was influenced by the normal 
hepatic enzyme levels and lack of severe liver injury. After 
6 months of follow-up the patient was well, and repeated 
blood analysis remained normal. Her rheumatoid arthritis was 
monitored throughout on the basis of the American College 
of Rheumatology criteria.
Case 2
A 49-year-old female with a medical history of infertility, 
obesity (body mass index = 31) and hypertension controlled 
by atenolol. The patient was also known to have nonalco-
holic fatty liver disease (NAFLD) due to being overweight, 
confirmed by liver sonography, with normal liver function 
tests. She had received no treatment for the NAFLD. She 
had a 12-year history of rheumatoid arthritis, treated in 
the past with MTX and NSAIDs with only mild improve-
ment. Complete blood count and biochemical data were 
all within the normal ranges (including GOT 16 U/L, GPT 
16 U/L, LDH 364 U/L, and GGT 21 U/L).
Due to exacerbation of the signs and symptoms of 
rheumatoid arthritis, the patient was treated with 100 mg/day 
anakinra by subcutaneous injection, starting in November 
2009. In January 2010 she complained of fatigue and 
laboratory examination at that time revealed elevated levels 
of liver enzymes (GOT 30 U/L, GPT 50 U/L, LDH 584 U/L, 
ALP 161 U/L, and GGT 85 U/L; however, serum bilirubin 
and amylase levels were normal. There were no significant 
hematological changes (white blood cells, hemoglobin, 
and platelet counts). No coagulation abnormalities 
were detected and urinalysis was normal. Antinuclear 
antibody, anti-liver-kidney mircosome antibodies, serum 
hepatitis B surface antigen, anti-hepatitis C virus, human 
immunodeficiency virus, immunoglobulin M for Epstein-
Barr virus/cytomegalovirus, and anti-hepatitis A virus were 
all negative. Serum ferritin, ceruloplasmin, and serum 
thyroid-stimulating hormone levels were within normal 
limits. Physical examination showed an overweight woman 
with mild hepatosplenomegaly, but the remainder of the 
examination was unremarkable and there were no other 
stigmata of chronic liver disease. Repeated echogram of the 
upper abdomen showed fatty liver and hepatosplenomegaly. 
Liver biopsy in February 2010 showed macrovesicular 
steatosis in 80% of the biopsy volume, with focal 
necrosis of hepatocytes and mild inflammatory infiltrate 
of lymphocytes around the necrotic areas and the liver 
sinusoids (Figure 2). It further showed intraportal fibrosis 
and perisinusoidal fibrosis. On the basis of these findings, 
anakinra was discontinued after 2 months of administration.  Figure 1 Case 1: areas of hemorrhagic necrosis and steatosis.Clinical Pharmacology: Advances and Applications 2011:3 submit your manuscript | www.dovepress.com
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She resumed treatment with NSAIDs and steroids, and 
refused any further treatment with biological drugs. After 
discontinuation of anakinra, her fatigue disappeared within 
20 days, and the biochemical data improved gradually. 
Her rheumatoid arthritis was monitored throughout in 
accordance with the American College of Rheumatology 
criteria.
Discussion
This paper reports two women with active rheumatoid arthritis 
refractory to standard therapies. Due to ongoing complaints 
and progressive arthritis and arthralgia, associated with active 
inflammatory parameters, one woman was eventually treated 
with tocilizumab and the other with anakinra. Treatment 
with these drugs resulted in significant improvement in the 
rheumatoid signs and symptoms in both patients. As part 
of the routine protocol, hepatic side effects were carefully 
assessed. Blood tests and liver imaging indicated toxic liver 
effects in both women. Adverse hepatic effects of tocilizumab 
and anakinra are well described in rheumatoid arthritis 
patients.1–3,5,7 Similar to other reports in the literature, alanine 
transaminase elevation in these cases was not associated with 
clinically significant increases in direct bilirubin nor was 
it associated with clinical evidence of hepatic failure.1 To 
confirm that the hepatotoxicity was, indeed, drug related, an 
extensive search was undertaken for other causes of acute and 
chronic liver injury, and no such causes were found in either 
woman. This step is extremely important in such cases, since 
autoimmune hepatitis in association with rheumatoid arthritis 
is a well-known phenomenon. Moreover, NAFLD and 
nonalcoholic steatohepatitis were evident in the cases. This 
could have been related, at least in part, to the overweight 
and past exposure to prolonged steroid therapy in both our 
patients. The presence of splenomegaly in both cases can also 
extend the etiologic differential diagnosis and include Felty’s 
syndrome, among others.1,4 Moreover, splenomegaly could 
be a predictor of cirrhosis, a reactive finding in longstanding 
immune disorders or as part of the metabolic syndrome.8
To completely exclude autoimmune hepatitis, evaluate 
drug toxicity, and assess the severity of liver injury, liver 
biopsy was performed in both cases. In both patients, the 
biopsy showed similar findings, consistent with drug injury. 
Those findings included focal necrosis of hepatocytes, 
with steatosis and early fibrosis. Inflammatory infiltrates 
were prominent in the anakinra-treated patient but not in 
the patient treated with tocilizumab. However, plasma cell 
infiltration was not seen and therefore autoimmune hepatitis 
could be excluded. In the absence of autoimmune hepatitis, 
focal necrosis of hepatocytes is very suggestive of drug 
toxicity; hepatocyte necrosis is also not common in 
NAFLD. Tocilizumab toxicity, however, is associated with 
hemorrhages but not with inflammatory infiltrates. FibroTest 
(Assistance publique – Hôpitaux de Paris, Paris, France) is a 
noninvasive tool recently developed to evaluate liver injury. 
This test was used in the tocilizumab-treated patient to assess 
liver injury and to serve as a noninvasive follow-up tool in 
the presence of normal levels of liver enzymes. It showed a 
necroinflammatory activity of A1–2 and was staged as F1–2. 
Thus, the findings of focal hepatocyte necrosis surrounded 
by either hemorrhages or inflammatory infiltrates in the 
patients were considered as direct histological evidence of 
drug toxicity related to the tocilizumab and anakinra. It has 
been suggested that the hepatic necrosis due to anakinra is a 
T-cell-dependent apoptotic immune-mediated response.9,10
The mechanism by which tocilizumab and anakinra 
are implicated in the pathogenesis of the fatty infiltrate 
formation is unclear. A role for the adipocytokines, leptin, 
plasminogen activator inhibitor-1, and insulin resistance 
has been offered to provide an etiopathological link.8,11,12 
However, more studies are needed to confirm this complex 
mechanism in humans.
Discontinuation of anakinra in Case 2 led to a rapid 
normalization of liver enzymes. In the other case, treated 
with tocilizumab, there was only hepatosplenomegaly but 
with completely normal liver enzymes. Cessation or dosage 
reduction of tocilizumab has been reported to result in 
improvement in liver enzyme levels. In spite of the toxic effect 
demonstrated in Case 1, tocilizumab treatment was continued, 
in view of a lack of response to other drugs, the good response 
Figure 2 Case 2: macrovesicular steatosis in 80% of the biopsy volume with focal 
necrosis of hepatocytes and lymphocytic infiltrates.Clinical Pharmacology: Advances and Applications
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to tocilizumab, and the insignificant histological liver injury. 
After 6 months of follow-up the patient remains well.
Conclusion
As more and more patients are being treated with tocilizumab 
and anakinra who develop liver toxicity, it is recommended 
that a full assessment of liver injury take place and the 
decision to continue or discontinue the drug be carefully 
considered. More series with long-term follow-up are needed 
to develop a management strategy.
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